Kathleen Tregoning
Director/Board Member at SPERO THERAPEUTICS, INC.
Net worth: 527 369 $ as of 2024-04-29
Profile
Kathleen Tregoning is currently an Independent Director at Spero Therapeutics, Inc. since 2021 and the Chief Corporate Affairs Officer at Cerevel Therapeutics Holdings, Inc. since 2020.
Previously, she served as the Executive Vice President-External Affairs at Sanofi from 2017 to 2020.
She also held the position of Senior Vice President-Corporate Affairs at Biogen France SAS.
Ms. Tregoning completed her undergraduate degree at Stanford University and her graduate degree at Harvard Kennedy School of Government.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2024-01-18 | 10,666 ( 0.01% ) | 448 719 $ | 2024-04-29 | |
SPERO THERAPEUTICS, INC.
0.10% | 2024-05-28 | 55,000 ( 0.10% ) | 78 650 $ | 2024-04-29 |
Kathleen Tregoning active positions
Companies | Position | Start |
---|---|---|
CEREVEL THERAPEUTICS HOLDINGS, INC. | Public Communications Contact | 2020-06-30 |
SPERO THERAPEUTICS, INC. | Director/Board Member | 2021-10-10 |
Former positions of Kathleen Tregoning
Companies | Position | End |
---|---|---|
SANOFI | Public Communications Contact | 2020-02-29 |
Biogen France SAS
Biogen France SAS BiotechnologyHealth Technology Biogen France SAS engages in research and development of biotechnology. The company was founded in 1994 and is headquartered in Paris, France. | Corporate Officer/Principal | - |
Training of Kathleen Tregoning
Stanford University | Undergraduate Degree |
Harvard Kennedy School of Government | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 3 |
---|---|
SANOFI | Health Technology |
SPERO THERAPEUTICS, INC. | Health Technology |
CEREVEL THERAPEUTICS HOLDINGS, INC. | Health Technology |
Private companies | 1 |
---|---|
Biogen France SAS
Biogen France SAS BiotechnologyHealth Technology Biogen France SAS engages in research and development of biotechnology. The company was founded in 1994 and is headquartered in Paris, France. | Health Technology |
- Stock Market
- Insiders
- Kathleen Tregoning